We aimed to assess the association between pregnancy and occurrence of diabetes-related complications in women with type 1 diabetes (T1D). Females 16-40 years old in the T1D Exchange clinic registry completing an initial questionnaire during 2011-13 and repeating it between 2016-18 (N=497; age 22±5 years, duration 12 [6,17] years, 87% non-Hispanic White) were categorized into 2 cohorts: first pregnancy during 2011-13 (preg; n=28) and never pregnant (never; n=469). No participants had complications reported at baseline. Funduscopic exam data were not uniformly available. There was a trend for lower HbA1c 5 years after study enrollment in the preg group (7.3%±1.3%) compared with the never group (7.9%±1.4%), P=0.14 adjusted for age, race/ethnicity, and body mass index. Both albuminuria and nephropathy within 5 years of study enrollment were found at higher frequency in the women who had never been pregnant (Table). Rates of neuropathy within 5 years of enrollment were similar between the groups. While rates of cardiovascular disease within 5 years of study enrollment were low for both groups (0 in preg group and 2 participants in never group), the pregnant cohort despite having lower A1c had higher frequency of some cardiovascular disease risk factors (e.g., obesity). In persons with T1D without reported complications at enrollment, pregnancy was not associated with new complication development 5 years after delivery.
graphic
View largeDownload slide
Disclosure

S. Polsky: Consultant; Self; Jaeb Center for Health Research. Research Support; Self; Barbara Davis Center for Diabetes, Children's Diabetes Foundation, Dexcom, Inc., Eli Lilly and Company, JDRF, Leona & Harry Helmsley Charitable Trust, National Institute of Diabetes and Digestive and Kidney Diseases, Sanofi US. N.C. Foster: None. S. DuBose: None. S. Agarwal: None. S. Lyons: None. A.L. Peters: Advisory Panel; Self; Abbott, Becton, Dickinson and Company, Bigfoot Biomedical, Eli Lilly and Company, Lexicon Pharmaceuticals, Inc., Livongo Health, MannKind Corporation, Medscape, Merck & Co., Inc., Omada Health, Inc., OptumRx, Inc., Sanofi US, Zafgen, Inc. Research Support; Self; AstraZeneca, Dexcom, Inc., Jaeb Center for Health Research, MannKind Corporation, National Institute of Diabetes and Digestive and Kidney Diseases. Speaker's Bureau; Self; Novo Nordisk Inc. G.I. Uwaifo: None. L. DiMeglio: Research Support; Self; Amgen Inc., Caladrius Biosciences, Inc., Janssen Research & Development, Medtronic, Sanofi. Other Relationship; Self; Dexcom, Inc. J. Sherr: Advisory Panel; Self; Bigfoot Biomedical, Eli Lilly and Company, Insulet Corporation. Consultant; Self; Lexicon Pharmaceuticals, Inc., Medtronic, Sanofi. Research Support; Self; Dexcom, Inc., Insulet Corporation. C.J. Levy: Advisory Panel; Self; Novo Nordisk A/S, Sanofi. Employee; Spouse/Partner; Allergan.

Funding

The Leona M. and Harry B. Helmsley Charitable Trust

© 2019 by the American Diabetes Association.
2019
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.